Stock AMBS AMARANTUS BIOSCIENCE HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Amarantus BioScience Holdings, Inc.

Equities

AMBS

US02300U2050

Market Closed - OTC Markets
Other stock markets
 02:41:42 2024-07-05 pm EDT 		5-day change 1st Jan Change
0.0001 USD 0.00% Intraday chart for Amarantus BioScience Holdings, Inc. 0.00% -80.00%
2022 Sector Update: Financial Stocks Still Adding to Wednesday Declines MT
2020 Todos Medical Ltd. (OTCPK:TOMD.F) completed the acquisition of remaining 80.01% stake in Breakthrough Diagnostics Inc. from Amarantus BioScience Holdings, Inc. CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Sector Update: Financial Stocks Still Adding to Wednesday Declines
MT
Amarantus BioScience : Notification of Late Filing
PU
Amarantus BioScience : Todos Medical Completes Acquisition of Breakthrough Diagnostics, Gains Full Rights to the Alzheimer’s Blood Diagnostic LymPro™ Test from Amarantus
AQ
Todos Medical Ltd. (OTCPK:TOMD.F) completed the acquisition of remaining 80.01% stake in Breakthrough Diagnostics Inc. from Amarantus BioScience Holdings, Inc.
CI
Emerald Organic Products : Restructures Joint Venture Agreement With Todos Medical by Entering Joint Collaboration Agreement
AQ
Amarantus BioScience : Todos Medical and 3DMed Enter Into Coronavirus (COVID-19) and Influenza A/B Testing Kit Distribution Agreement in US and Israel
AQ
Amarantus BioScience : Announces Subsidiary MANF Therapeutics Enters Into Material Transfer Agreement with Dyadic International
AQ
Amarantus Releases Letter to Shareholders
GL
Amarantus Acquires Majority Interest in CBD Wellness Company Hempori
GL
Amarantus BioScience Holdings, Inc. acquired majority interest in Hempori, Inc. for $0.38 million.
CI
Emerald Organic Products : Amarantus Completes Sublicense of ESS, MANF and PhenoGuard to Emerald Organic Products
AQ
Amarantus Completes Sublicense of ESS, MANF and Phenoguard to Emerald Organic Products
CI
Amarantus to Present at 12th Annual LD Micro Main Event
GL
Amarantus Subsidiary Elto Pharma Receives Notice of Allowance Covering Use of Eltoprazine Combined with CBD to Treat Parkinson’s Disease
GL
Amarantus Announces Issuance of Chinese Patent Covering the Use of MANF and CDNF in Retinal Disorders for Subsidiary MANF Therapeutics
GL
Amarantus Announces Issuance of Chinese Patent Covering the Use of MANF and CDNF in Retinal Disorders for Subsidiary Manf Therapeutics
CI
Amarantus Provides Recapitalization Update to Shareholders
GL
Amarantus Enters Into Agreement to License Diverse Therapeutics Portfolio to CBD-focused Emerald Organic Products
GL
Amarantus Bioscience Holdings, Inc. Enters into Agreement to License Diverse Therapeutics Portfolio to CBD-Focused Emerald Organic Products with Emerald Organic Growth, Inc
CI
Coeptis Pharmaceuticals, Inc. terminated the acquisition of Elto Pharma, Inc. from PsychoGenics Inc. and Amarantus BioScience Holdings, Inc..
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AMBS Stock
  4. News Amarantus BioScience Holdings, Inc.